Known targets — ChEMBL curated mechanism
ABCC9ABL1ACEACHEACVR1ADORA1ADORA2AADORA2BADORA3ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALOX5ATP4AATP4BBCRBTKCACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGCRBNCUL4ACXCR1CXCR2DDB1DDCDHFRDPP4DRD2DRD3DRD4EGFRERBB2ERBB4ESR1ESR2FDPSFKBP1AFLT1FLT3FLT4GARTGHSRGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5GRIN2AGSK3AGSK3BHDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IDH1IDH2IMPA1ITGA2BITGB3JAK1JAK2JAK3KCNJ11KCNK3KCNK9KDRKITMEN1METMMP1MMP13MMP7MMP8NANOD2NS5bODC1OPG057OPRD1OPRK1OPRM1PPARP1PARP2PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PKLRPPARDPPATPTGS1PTGS2RBX1ROCK1ROCK2RRM1RRM2RRM2BSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC10A2SLC5A2SLC6A2SLC6A3SLC6A4SLC9A3SYKTACR1THRATHRBTOP1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYK2TYMSVDRampCblablaT-3blaT-4blaT-5blaT-6blaUOE-1dacAdacBdacCfolAfolPftsIgyrAgyrBileSmecAmrcAmrcBmrdAparCparEpbp2pbp4pbpApbpFrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUthyAykgMykgO
The experimentally established mechanism targets of Tetroquinone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 known ✓ | O00255 | 2/20 | 0.90 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 2/20 | 0.90 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.90 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.90 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.90 |
| ▸ | BLM | P54132 | 1/20 | 0.90 |
| ▸ | APAF1 | O14727 | 1/20 | 0.44 |
| ▸ | TDP2 | O95551 | 1/20 | 0.44 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | SENP1 | Q9P0U3 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tetroquinone SCHEMBL10609095 | 1.00 | KDM4E (1.00) | KDM4EALDH1A1TDP1LMNAHSD17B10 | |
| Tetroquinone SCHEMBL167587 | 0.95 | KDM4E (1.00) | KDM4EALDH1A1TDP1LMNAHSD17B10 | |
| Tetroquinone SCHEMBL30687945 | 0.90 | KDM4E (0.90) | KDM4EALDH1A1TDP1LMNAHSD17B10 | |
| Tetroquinone SCHEMBL28458147 | 0.90 | KDM4E (0.90) | KDM4EALDH1A1TDP1LMNAHSD17B10 | |
| Tetroquinone SCHEMBL29249657 | 0.90 | KDM4E (0.90) | KDM4EALDH1A1TDP1LMNAHSD17B10 | |
| Tetroquinone SCHEMBL30687946 | 0.90 | KDM4E (0.90) | KDM4EALDH1A1TDP1LMNAHSD17B10 | |
| Tetroquinone SCHEMBL31259898 | 0.90 | KDM4E (0.90) | KDM4EALDH1A1TDP1LMNAHSD17B10 | |
| Tetroquinone SCHEMBL10666573 | 0.90 | KDM4E (0.90) | KDM4EALDH1A1TDP1LMNAHSD17B10 | |
| Tetroquinone SCHEMBL28209010 | 0.90 | KDM4E (0.90) | KDM4EALDH1A1TDP1LMNAHSD17B10 | |
| SCHEMBL13801532 | 0.90 | KDM4E (0.90) | KDM4EALDH1A1TDP1LMNAHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 174 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119977819-A | Organic electric energy transfer eutectic crystal with near infrared light thermal characteristics and preparation method of light heat storage fiber thereof | 苏州大学 | 2025-05-13 | — | — | CN | claimed |
| CN-118419976-A | Lamellar vanadium-based material capable of regulating interlayer spacing by utilizing solvent molecules/electrochemical active organic molecules, and preparation method and application thereof | 石河子大学 | 2024-08-02 | — | — | CN | claimed |
| CN-117434125-A | Electrochemical biosensor based on copper-based conductive metal organic framework modification and preparation method and application thereof | 中国科学院大连化学物理研究所 | 2024-01-23 | — | — | CN | claimed |
| EP-4304638-A1 | USES OF AMPHIPHILES IN IMMUNE CELL THERAPY AND COMPOSITIONS THEREFOR | Elicio Therapeutics, Inc. (US) | 2024-01-17 | — | — | EP | claimed |
| US-11859047-B2 | Polycarbonate resin composition and article including the same | LG CHEM, LTD. (KR) | 2024-01-02 | — | — | US | claimed |
| US-20230380457-A1 | Materials and Methods for Extending Shelf-Life of Foods | JP LABORATORIES, INC. | 2023-11-30 | — | — | US | claimed |
| EP-4280882-A2 | MATERIALS AND METHODS FOR EXTENDING SHELF-LIFE OF FOODS | JP LABORATORIES, INC. (US) | 2023-11-29 | — | — | EP | claimed |
| US-20230363426-A1 | Materials and Methods for Extending Shelf-Life of Foods | JP LABORATORIES, INC. | 2023-11-16 | — | — | US | claimed |
| US-11793220-B2 | Materials and methods for extending shelf-life of foods | JP LABORATORIES, INC. (US) | 2023-10-24 | — | — | US | claimed |
| CN-116916755-A | Materials and methods for extending the shelf life of food products | JP实验室公司 | 2023-10-20 | — | — | CN | claimed |
| EP-3097169-A1 | CONSUMER PRODUCT COMPOSITIONS | The Procter & Gamble Company (US) | 2016-11-30 | — | — | EP | claimed |
| US-20150210963-A1 | Systems and Methods for Treating a Surface | THE PROCTER & GAMBLE COMPANY | 2015-07-30 | — | — | US | claimed |
| US-20150210964-A1 | Consumer Product Compositions | THE PROCTER & GAMBLE COMPANY | 2015-07-30 | — | — | US | claimed |
| WO-2015112667-A1 | SYSTEMS AND METHODS FOR TREATING A SURFACE | THE PROCTER & GAMBLE COMPANY (US) | 2015-07-30 | — | — | WO | claimed |
| WO-2015112671-A1 | CONSUMER PRODUCT COMPOSITIONS | THE PROCTER & GAMBLE COMPANY (US) | 2015-07-30 | — | — | WO | claimed |
| US-7384533-B2 | Electrolytic processes with reduced cell voltage and gas formation | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2008-06-10 | — | — | US | claimed |
| WO-2003035941-A2 | ELECTROLYTIC PROCESSES WITH REDUCED CELL VOLTAGE AND GAS FORMATION | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2003-05-01 | — | — | WO | claimed |
| EP-0801089-A1 | Preparation of branched polycarbonates | THE COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 1997-10-15 | — | — | EP | claimed |
| US-5663029-A | DEVELOPMENT OF LATENT IMAGE, TRANSFERRING TO FORM RECORDING SHEETS, COATING A SUBSTRATE USING POLYMERS | XEROX CORPORATION (US) | 1997-09-02 | — | — | US | claimed |
| EP-0667245-A1 | Recording sheets containing alcohols and saccharides | XEROX CORPORATION (US) | 1995-08-16 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150210963-A1 | Systems and Methods for Treating a Surface | HMBS, PPOX, TTPA | MEN1 4665/4885KDM4E 4428/4885ALDH1A1 1283/4885 |
| US-20150210964-A1 | Consumer Product Compositions | NQO1, TYR, ETFA | MEN1 3836/4885KDM4E 3331/4885ALDH1A1 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.